A study suggests a class of medications used to treat type 2 diabetes may also reduce the risk of colorectal cancer (CRC). "Our results clearly demonstrate that GLP-1 RAs are significantly more effective than popular anti-diabetic drugs, such as Metformin or insulin, at preventing the development of CRC," said Nathan Berger. Glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, are medications to treat type 2 diabetes. Usually given by injection, they can lower blood-sugar levels, improve insulin sensitivity and help manage weight. They've also been shown to reduce the rates of major cardiovascular ailments. Importantly the protective effect of GLP-1 RAs...
